Skip to main content
. 2023 May 15;19(1):2210046. doi: 10.1080/21645515.2023.2210046

Figure 1.

Figure 1.

Key events in the clinical development of tisagenlecleu.

ALL, acute lymphoblastic leukemia; CAR-T, chimeric antigen receptor T cell; DLBCL, diffuse large B-cell lymphoma; EMA, European Medicines Agency; EU, European Union; US FDA, United States Food and Drug Administration; FL, follicular lymphoma; ODAC, Oncologic Drugs Advisory Committee; RMAT, regenerative medicine advanced therapy; r/r, relapsed or refractory.